secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2023-01-23T23:59:59+00:00
Accession:  0001193125-23-012556
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan receives FDA clearance for three INDs in solid tumor program, including T-Plex and two MAGE-A1-targeting TCRs
--------------------------------------------------------------------------------

- FDA cleared primary IND T-Plex enabling customized multiplexed TCR-T combinations based on tumor target/HLA expression.
- Secondary INDs for TSC-204-A0201 and TSC-204-C0702 targeting MAGE-A1 on HLA A*02:01 and C*07:02 respectively.
- MAGE-A1 overexpressed in 45% of head and neck cancers and 50% of melanoma, cervical, and non-small cell lung cancers.
- TScan plans multicenter Phase 1 trial; screening protocol expected in Q2 2023, initial clinical data by end of 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000119312523012556/0001193125-23-012556-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000119312523012556/d449073d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-012556

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer